Abstract:Type 1 diabetes (T1D) is a chronic, multifactorial autoimmune disorder that is characterized by the progressive immune destruction to pancreatic β cells, which begins years before clinical onset. The latest survey showed that there are nearly 100 million patients with diabetes in China.1 At present, the therapy of this disease can not be carried out effectively aiming at etiology. Patients with T1D rely on insulin replacement treatment and bear huge risks of long-term complications and severe hypoglycemia. Biologic therapies are relatively innovative treatments. Unlike conventional medicines that modify the immune system as a whole, biologics affect specific immune component. Theoretically, this targeted approach is not only more specific in its effects but also less likely to result in adverse events. Therefore, biologic therapies have become a new research hotspot of T1D treatment. They have been increasingly used in the treatment of autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease) and could offer new hope for autoimmune diabetic patients. Herein we concentrate on the recent clinical trials of biologic therapies in T1D (Table 1).Table 1: Main biologics used in patients with T1DDIAMYD (GAD-ALUM) Diamyd, recombinant human glutamic acid decarboxylase (rhGAD65), is a specific isoform of GAD that is expressed in human pancreatic β cells and a major antigen targeted by autoreactive T lymphocytes in T1D. It is used as an antigen-specific immune modulator. Preclinical studies have shown that it may delay or prevent autoimmune destruction of pancreatic islet cells by inducing immune tolerance.2 In a trial, 20 μg doses of GAD-alum on study days 1 and 30 were administered to patients with T1D within 18 months of diagnosis. Preservation of C-peptide responses at 30 months was only observed in patients treated within 6 months of diagnosis, which implied the importance of disease stage for GAD-alum therapy.3 In a phase II trial of patients with latent autoimmune diabetes in adults (LADA), GAD-alum preserved fasting C-peptide (FCP) levels at 24 weeks compared with placebo in the 20 μg group.4 However, GAD-alum was ineffective in two randomized placebo-controlled T1D clinical trials. Treatment with GAD-alum did not significantly reduce the loss of insulin secretion or improve clinical outcomes during 1 year5 or over a 15-month period.6 Antigen-special therapy is effectively in animal models. Nonetheless, translating therapies to the clinic is a challenge. OTELIXIZUMAB/TEPLIZUMAB Otelixizumab/Teplizumab is a humanized anti-CD3 monoclonal antibody (mAb), which promotes immune tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. Anti-CD3 mAb has achieved success in the phase I/II clinical trial in which teplizumab improves insulin response and metabolic control for one year.7 Subsequent studies have also demonstrated that the perseveration of C-peptide response can be maintained, and that insulin doses and hemoglobin A1C (HbA1c) can be reduced even 5 years after treatment in many patients with recent onset T1D.8-10 However, the latest phase III trial has suffered setbacks and did not meet its primary end point possibly due to inadequate doses or choice of inappropriate end points.11 Thus, these studies indicate a narrow therapeutic window of anti-CD3-based therapies. The newly updated phase III study verified that teplizumab (14-day full-dose) reduced the loss of C-peptide responses at 2 years versus placebo.12 Moreover, 2-year results from the Protégé trial12 and the AbATE Study Team13 both showed that patients with better metabolic and immunologic features at entry would have greater C-peptide preservation. ABATACEPT T cells activation requires two critical signals including the antigen-specific T cell receptor (TCR) signal and a second signal through costimulation molecules. Abatacept selectively binds to CD80/86 on antigen presenting cells thereby blocking the interaction with CD28 on the T cell. It is a selective costimulation modulator, which could block the interaction between the antigen-presenting cell's CD80/86 ligand and the CD28 ligand on the T cell. It could decrease T cell proliferation and cytokine production. A recent trial in T1D patients showed that costimulation modulation with Abatacept reduced the decline of C-peptide levels after 2 years intervention.14 However, the efficacy lessened with time despite continued treatment.14 Abatacept for prevention of abnormal glucose tolerance and diabetes in relatives of T1D at high risk is under recruiting (NCT01773707). RITUXIMAB Rituximab is a chimeric monoclonal antibody that selectively deletes B lymphocytes. Rituximab was authorized for the treatment of active rheumatoid arthritis unresponsive to DMARDs and anti-TNF-α agents. It has been used successfully for systemic lupus erythematosis.15 It has been shown that Rituximab could prevent and even reverse diabetes in a proportion of NOD mice.16 A recent phase II clinical trial of Rituximab in patients newly diagnosed with T1D demonstrated that a four-dose course of Rituximab effectively delayed the loss of C-peptide responses, with lower HbA1c levels and reduced exogenous insulin doses.17 However, several months later, B cells returned to the circulation and β cell destruction resumed.17 The effects were best within 3 months and gradually declined during the course of 1 year. Unfortunately, the effects on C-peptide responses were transient. Over 30 months after intervention, the rate of decline of C-peptide was parallel between groups, but shifted by 8.2 months in Rituximab group.18 ANAKINRA/CANAKINUMAB Cytokines have been known to exert an effect on the development of diabetes. Interleukin (IL)-1β is a central immune regulator produced by monocytes that are known to infiltrate the pancreatic islets in human insulitis and involve in β cell inflammation and apoptosis. Two multicenter, randomised, double-blind, placebo-controlled trials have shown that either Canakinumab (anti-IL-1β antibody) or Anakinra (IL-1 receptor antagonist) did not slow down β cell decline.19 Since the combination of IL-1β blockade and anti-CD3 mAb resulted in a synergy in reversal of diabetes in NOD mice,20 IL-1 blockade might be more effective in combination with treatment targeting adaptive immunity in autoimmune diabetes. ETANERCEPT Etanercept is a soluble tumour necrosises factor (TNF)-receptor fusion protein. This fusion protein binds to both TNF-α and TNF-β, and prevents them from interacting with their receptors. In a pilot study of new-onset pediatric patients with T1D comparing Etanercept with placebo for 24 weeks, Etanercept is administered as a subcutaneous injection at a dose of 0.4 mg/kg up to a maximum dose of 25 mg/dose twice weekly.21 Increased endogenous insulin production and improved metabolic control was observed, suggesting preservation of β cell function.21 A case report showed that Etanercept preserved C-peptide level for up to 11 years in one LADA patient and that his HbA1c levels have remained less than 6.5% all the time.22 Further studies of longer duration and larger group size will be required to confirm the efficacy of Etanercept. COMBINATION TREATMENT Currently, we carried out clinical trials in T1D with single biologic reagent, which only showed a short term effect (Table 1). As a consequence of the pathogenesis of T1D involving many aspects, we cannot prevent or reverse it by blocking single pathway. Combination treatment of biological medicine has been proved effectively in NOD mice for T1D. For instance, combining anti-CD3 with nasal proinsulin exhibited a synergy that combination treatment can reverse diabetes with much higher efficacy than with either monotherapy in two murine diabetes models.23 Anti-CD20 and oral anti-CD3 combination therapy is better than anti-CD20 monotherapy for regaining normoglycemia in diabetic NOD mice.24 Exenatide improved reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of β cells.25 Along these lines, a pilot trial in children and adolescents with T1D using GAD-alum (Diamyd) in combination with vitamin D and ibuprofen is recruiting participants (NCT01785108). CONCLUSIONS Biologic therapies have been successful in other autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosis and autoimmune thyroid disease. How far are they from T1D treatment? Both positive and negative results are from clinical trials of biologic therapy in T1D. It can maintain β cell function in the short term. However, the protective effects gradually lose during long time follow-up. Considering the heterogeneity of T1D, the diversity of islet cell antigens, the complexity of the autoimmune process, monotherapy might not be able to prevent or reverse T1D progression completely. Animal studies indicated that combination treatment has made a progress. Nonetheless, the clinical based evidence for combination therapy is insufficient. Further randomized controlled trials are required to confirm the efficacy of biologics, determine details of administration doses together with frequence, and provide more information on adverse events. With regard to the immunologic pathogenesis of T1D, biologic therapy is the unique etiological treatment. We believe that biologic therapy in T1D will thrive in the future.

Abnormal cannabidiol ameliorates inflammation preserving pancreatic beta cells in mouse models of experimental type 1 diabetes and beta cell damage

The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease

Ginsenoside Rg1 Improves Inflammation and Autophagy of the Pancreas and Spleen in Streptozotocin-Induced Type 1 Diabetic Mice.

Beta cell specific cannabinoid 1 receptor deletion counteracts progression to hyperglycemia in non-obese diabetic mice

Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans

Anti-CD20 Therapy Ameliorates Β Cell Function and Rebalances Th17/Treg Cells in NOD Mice

Essential Roles Of Tgf-Beta In Anti-Cd3 Antibody Therapy: Reversal Of Diabetes In Nonobese Diabetic Mice Independent Of Foxp3(+) Cd4(+) Regulatory T Cells

Conditioned Media from Deer Antler Stem Cells Effectively Alleviate Type 1 Diabetes Mellitus Possibly via Inhibiting the NF-κB Signaling Pathway

Inhibition of CD226 Co-Stimulation Suppresses Diabetes Development in the NOD Mouse by Augmenting Tregs and Diminishing Effector T Cell Function

Cannabidiol and Beta-Caryophyllene Combination Attenuates Diabetic Neuropathy by Inhibiting NLRP3 Inflammasome/NFκB through the AMPK/sirT3/Nrf2 Axis

Transient B-cell depletion and regulatory T-cells mediation in combination with adenovirus mediated IGF-1 prevents and reverses autoimmune diabetes in NOD mice

Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy

Orally delivered all-trans-retinoic acid- and transforming growth factor-β-loaded microparticles ameliorate type 1 diabetes in mice

2131-P: Dextran Sulfate and HGF Ameliorate Type 1 Diabetes

A Novel Tolerogenic Antibody Targeting Disulfide-Modified Autoantigen Effectively Prevents Type 1 Diabetes in NOD Mice

Biologic Therapies in Type 1 Diabetes: How Far Are They from Us?

Aberrant TNF signaling in pancreatic lymph nodes of patients with Type 1 Diabetes

Adipose-derived stem cells alleviate liver injury induced by type 1 diabetes mellitus by inhibiting mitochondrial stress and attenuating inflammation

Dextran Sulfate Protects Pancreatic Β-Cells, Reduces Autoimmunity and Ameliorates Type 1 Diabetes

Adipose Tissue-Derived Mesenchymal Stromal Cells Modulate Inflammatory Response and Improve Allograft Islet Transplant in Mice Model of Type 1 Diabetes

PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy